Firm is eligible to another $525 million for these two early-stage compounds.

S*BIO will initially receive $25 million as a combination of cash and stock under a collaboration with Onyx Pharmaceuticals covering JAK2 inhibitors, SB1518 and SB1578. The total value of the deal could climb to $550 million and will include double-digit royalties.

While SB1518 is currently in Phase I for myelofibrosis and other myeloproliferative diseases, JAK2 inhibitors are implicated in various illnesses including cancer and autoimmune diseases. SB1578 is in preclinical development.

S*BIO will perform all development activities for both compounds, and Onyx can elect to exercise its exclusive options at certain predetermined stages. Each option converts into an exclusive license for development and commercialization rights in all indications in the U.S., Canada, and Europe. If exercised, Onyx will assume all associated development costs.

If S*BIO choses to co-fund these expenses, it will receive enhanced royalties. S*BIO retains rights to develop and commercialize SB1518 and SB1578 in the rest of the world.


Previous articleResearchers Discover Trigger for Cell Death Signaling Mechanism
Next articleChiome and Chugai Enter mAb Discovery Collaboration